203
Participants
Start Date
November 1, 2022
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
MK-1045
MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Each 4 week treatment cycle is followed by a 2-week treatment-free interval
RECRUITING
The First Hospital of Harbin ( Site 0005), Harbin
ACTIVE_NOT_RECRUITING
The Affiliated Hospital of Xuzhou Medical University ( Site 0007), Xuzhou
RECRUITING
Hematology Hospital of Chinese Academy of Medical Sciences ( Site 0001), Tianjin
COMPLETED
The Children's Hospital of Zhejiang University School of Medicine ( Site 0009), Hangzhou
RECRUITING
The Second Affiliated Hospital of Third Military Medical University ( Site 0008), Chongqing
RECRUITING
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology ( Site 0010), Wuhan
RECRUITING
Tongji Hospital affiliated to Tongji Medical College of HUST ( Site 0006), Wuhan
RECRUITING
Henan Cancer Hospital-hematology department ( Site 0002), Zhengzhou
RECRUITING
Southern Medical University Nanfang Hospital ( Site 0004), Guangzhou
COMPLETED
West China Second University Hospital, Sichuan University ( Site 0011), Chengdu
RECRUITING
The Second Hospital of Hebei Medical University ( Site 0003), Shijiazhuang
MSD R&D (China) Co., Ltd.
INDUSTRY